References
- Pirkle JL, Brody DJ, Gunter EW, et al. The decline in blood lead levels in the United States. The National Health and Nutrition Examination Surveys (NHANES). JAMA. 1994;272:284–291.
- Virji MA, Woskie SR, Pepper LD. Task-based lead exposures and work site characteristics of bridge surface preparation and painting contractors. J Occup Environ Hyg. 2009;6:99–112.
- Araujo J, Beelen AP, Lewis LD, et al. Lead poisoning associated with ayurvedic medications — five states, 2000–2003. MMWR Morb Mortal Wkly Rep. 2004;53:582–584.
- Bradberry S, Vale A. A comparison of sodium calcium edetate (edetate calcium disodium) and succimer (DMSA) in the treatment of inorganic lead poisoning. Clin Toxicol (Phila). 2009;47:841–858.
- Bradberry S, Vale A. Dimercaptosuccinic acid (succimer; DMSA) in inorganic lead poisoning. Clin Toxicol (Phila). 2009;47:617–631.
- Leggett RW. An age-specific kinetic model of lead metabolism in humans. Environ Health Perspect. 1993;101:598–616.
- O'Flaherty EJ. Physiologically based models for bone-seeking elements. IV. Kinetics of lead disposition in humans. Toxicol Appl Pharmacol. 1993;118:16–29.
- U.S. EPA. Technical support document: parameters and equations used in the Integrated Exposure Uptake Biokinetic (IEUBK) model for lead in children. Washington (DC): Office of Solid Waste and Emergency Response U.S. Environmental Protection Agency, 1994. Available at: https://nepis.epa.gov/Exe/ZyNET.exe/P100MECY.TXT?ZyActionD=ZyDocument&Client=EPA&Index=1991+Thru+1994&Docs=&Query=&Time=&EndTime=&SearchMethod=1&TocRestrict=n&Toc=&TocEntry=&QField=&QFieldYear=&QFieldMonth=&QFieldDay=&IntQFieldOp=0&ExtQFieldOp=0&XmlQuery=&File=D%3A%5Czyfiles%5CIndex%20Data%5C91thru94%5CTxt%5C00000031%5CP100MECY.txt&User=ANONYMOUS&Password=anonymous&SortMethod=h%7C-&MaximumDocuments=1&FuzzyDegree=0&ImageQuality=r75g8/r75g8/x150y150g16/i425&Display=hpfr&DefSeekPage=x&SearchBack=ZyActionL&Back=ZyActionS&BackDesc=Results%20page&MaximumPages=1&ZyEntry=1&SeekPage=x&ZyPURL.
- Maiorino RM, Bruce DC, Aposhian HV. Determination and metabolism of dithiol chelating agents: VI. Isolation and identification of the mixed disulfides of meso-2, 3-dimercaptosuccinic acid with L-cysteine in human urine. Toxicol Appl Pharmacol. 1989;97:338–349.
- Maiorino RM, Akins JM, Blaha K, et al. Determination and metabolism of dithiol chelating agents: X. In humans, meso-2,3-dimercaptosuccinic acid is bound to plasma proteins via mixed disulfide formation. J Pharmacol Exp Ther. 1990;254:570–577.
- Maiorino RM, Aposhian MM, Xu ZF, et al. Determination and metabolism of dithiol chelating agents. XV. The meso-2,3-dimercaptosuccinic acid-cysteine (1:2) mixed disulfide, a major urinary metabolite of DMSA in the human, increases the urinary excretion of lead in the rat. J Pharmacology Exp Ther. 1993;267:1221–1226.
- Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology. 1995;97:23–38.
- Dart RC, Hurlbut KM, Maiorino RM, et al. Pharmacokinetics of meso-2,3-dimercaptosuccinic acid in patients with lead poisoning and in healthy adults. J Pediatr. 1994;125:309–316.
- Liang Y-Y, Marlowe C, Waddell WJ. Disposition of [14C]dimercaptosuccinic acid in mice. Fundam Appl Toxicol. 1986;6:532–540.
- Castellino N, Castellino P, Sannolo N, editors. Inorganic lead exposure: metabolism and intoxication. Boca Raton (FL): Lewis Publishers; 1995.
- Asiedu P, Moulton T, Blum CB, et al. Metabolism of meso-2,3-dimercaptosuccinic acid in lead-poisoned children and normal adults. Environ Health Perspect. 1995;103:734–739.
- Aposhian HV, Maiorino RM, Dart RC, et al. Urinary excretion of meso-2,3-dimercaptosuccinic acid in human subjects. Clin Pharmacol Ther. 1989;45:520–526.
- Aegis. Acsl Extreme (Version 3.0.2.1.). 2015; [cited 2016 Jan 12]. Available at: http://www.acslx.com/.
- IPCS, 2010. Characterization and application of physiologically based pharmacokinetic models in risk assessment [Internet]; [cited 2016 Jan 12]. Available at: http://www.inchem.org/documents/harmproj/harmproj/harmproj9.pdf.
- Aposhian HV, Aposhian MM. Meso-2, 3-dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu Rev Pharmacol Toxicol. 1990;30:279–306.
- Lowry JA. Oral chelation therapy for patients with lead poisoning [Internet]. 2010; WHO; [cited 2015 Nov 11]. Available at: http://www.who.int/selection_medicines/committees/expert/18/applications/4_2_LeadOralChelators.pdf.
- Smith DR, Flegal AR. Stable isotopic tracers of lead mobilized by DMSA chelation in low lead-exposed rats. Toxicol Appl Pharmacol. 1992;116:85–91.
- Khan DA, Qayyum S, Saleem S, Khan FA. Evaluation of lead body burden in occupational workers by lead mobilization test. J Pak Med Assoc. 2009;59:350–354.
- Bos PM, Zeilmaker MJ, van Eijkeren JC. Application of physiologically based pharmacokinetic modeling in setting acute exposure guideline levels for methylene chloride. Toxicol Sci. 2006;91:576–585.
- Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002;42:620–643.
- Tillotson JA, Boswell G, Kincannon L, et al. The biological fate of 14C-dimercaptosuccinic acid in monkeys and rabbits. Mil Med. 1989;154:444–449.